Shots:

• Y-mAbs has submitted the BLA the US FDA under the FDA’s Rolling Review process for naxitamab following the market closure on Mar 31- 2020
• The BLA submission is based on two P-II studies- 201 and 12-230 assessing the safety & efficacy of the therapy- which the company expects to present at a venue later this year
• Naxitamab is an investigational mAb- targeting GD2 having the potential to address the unmet medical needs of patients with relapsed/refractory high-risk neuroblastoma. The therapy was initially developed by MSK and exclusively licensed to Y-mAbs

Click here to­ read full press release/ article | Ref: Y-mAbs | Image: Y-mAbs